Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Toronto Stock Exchange  >  IMV Inc.    IMV   CA44974L1031

IMV INC.

(IMV)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Toronto Stock Exchange
01/20/2021 01/21/2021 01/22/2021 01/25/2021 01/26/2021 Date
4.63(c) 4.51(c) 4.69(c) 4.55(c) 4.51 Last
154 097 140 797 132 431 106 279 114 419 Volume
-1.28% -2.59% +3.99% -2.99% -0.88% Change
More quotes
Financials
Sales 2020 0,27 M 0,21 M 0,21 M
Net income 2020 -33,3 M -26,1 M -26,1 M
Net Debt 2020 - - -
P/E ratio 2020 -8,41x
Yield 2020 -
Sales 2021 1,46 M 1,15 M 1,15 M
Net income 2021 -37,5 M -29,3 M -29,3 M
Net Debt 2021 - - -
P/E ratio 2021 -7,05x
Yield 2021 -
Capitalization 315 M 247 M 247 M
Capi. / Sales 2020 1 165x
Capi. / Sales 2021 215x
Nbr of Employees 62
Free-Float 99,3%
More Financials
Company
IMV Inc. is a clinical stage biopharmaceutical company focused on developing cancer immunotherapies and vaccines against infectious diseases, including coronavirus disease 2019 (COVID-19). The Company develops cancer-targeted immunotherapies and vaccines based on the Company’s platform, DPX. The Company’s lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the platform with a cancer... 
More about the company
Notations Surperformance© of IMV Inc.
Trading Rating : Investor Rating :
More Ratings
All news about IMV INC.
01/04IMV : to Participate in Two Upcoming Investor Events
BU
2020UPDATE ON STOCK TO WATCH : Dual-Listed IMV Up Near 6% on TSX Early Tuesday
MT
2020MT NEWSWIRES STOCKS TO WATCH : Dual-Listed IMV Down 0.3% In US Pre-Market
MT
2020SECTOR UPDATE : Health Care Stocks Hang on for Small Advance
MT
2020SECTOR UPDATE : Health Care Stocks Maintaining Modest Monday Gains
MT
2020IMV : Says Preclinical Studies Shows Potential of COVID-19 Vaccine Candidate, Sh..
MT
2020Wall Street Set for Gains as Trump OKs Stimulus Package
MT
2020US Futures Higher as Trump OKs Stimulus Package
MT
2020IMV : Reports Update on COVID-19 Vaccine Program
BU
2020IMV : TMX Group, IMV, C-Suite at The Open
AQ
2020Dual-Listed IMV Says Durable Clinical Benefits Induced by Its T-Cell Therapy ..
MT
2020IMV : Durable Clinical Benefits Induced by IMV's T Cell Therapy in Combination W..
BU
2020SECTOR UPDATE : Health Care Stocks Mixed Premarket Thursday
MT
2020IMV's Survivin-targeted T Cell Therapy Shows "Durable Clinical Benefits" in P..
MT
2020IMV INC. BRIEF : Says Survivin-targeted T Cell Therapy Shows Durable Clinical Be..
MT
More news
News in other languages on IMV INC.
2020IMV : fournit une mise à jour sur son programme de vaccin COVID-19
2020IMV : reçoit des subventions de la part d'agences gouvernementales pour la phase..
2020IMV : annonce une mise-à-jour des progrès rapides de son programme de développem..
2020Spanien will schon bald Grundeinkommen einführen
2020IMV : Annonce la clôture d'un placement privé de 25,1 millions $
More news
Chart IMV INC.
Duration : Period :
IMV Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IMV INC.
Short TermMid-TermLong Term
TrendsBullishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 8,42 CAD
Last Close Price 4,55 CAD
Spread / Highest target 142%
Spread / Average Target 85,1%
Spread / Lowest Target -13,6%
EPS Revisions
Managers and Directors
NameTitle
Frederic Ors Chief Executive Officer & Non-Independent Director
Andrew J. Sheldon Chairman
Ryan Marshall Vice President-Project Management & Operations
Pierre Labbé Chief Financial Officer
Marianne Stanford Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
IMV INC.16.97%247
MODERNA, INC.40.71%58 169
LONZA GROUP AG6.79%50 766
CELLTRION, INC.-10.58%39 697
IQVIA HOLDINGS INC.2.15%35 090
SEAGEN INC.2.84%32 583